UBS Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $55

Benzinga · 1d ago
UBS analyst Michael Yee initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $55.